RLS103, a dry powder inhaled cannabidiol, uses an inhalation formulation technology coupled with a breath-powered device, both currently used in two FDA-approved products.
The RLS103 inhalation powder provides IV-like pharmacokinetics and contains synthetic CBD and FDKP, an FDA-approved inhalation excipient.
The Phase 1b/2a clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel study to evaluate the safety, tolerability, and efficacy of two doses of RLS103 in adult subjects with acute anxiety within SAD.
The primary endpoint of the study is safety and tolerability. The secondary endpoints are efficacy and changes in physiologic measures of anxiety following a simulated public speaking challenge conducted in a clinical setting.
The results from the Phase 1b/2a study will be used to facilitate the design of a larger, well-controlled, randomized safety and efficacy study intended for registration.
According to the Anxiety and Depression Association of America and the National Institute of Mental Health, Social Anxiety Disorder affects about 15 m adults in the US and is the second-most commonly diagnosed anxiety disorder.
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments.
Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference